Novocure sees FY24 revenue $605.2M, consensus $596.95M

The company said 2024 growth was primarily driven by its launch in France and improved approval rates in the U.S., which are now reflected in its revenue baseline. FY25 net revenue growth is expected to closely reflect growth in Optune Gio active patients. “Novocure (NVCR) is at an exciting inflection point as we continue to expand our multi-indication TTFields treatment platform. In 2024, we brought Optune Gio to more than 4,000 glioblastoma patients across the globe, earned FDA approval and launched Optune Lua in non-small cell lung cancer in the U.S., announced two additional successful Phase 3 trial readouts and released our next generation arrays,” said Ashley Cordova, CEO. “With two additional indication launches on the horizon, we are well positioned for 2025 and beyond. This progress demonstrates our steadfast commitment to our patient-forward mission: together with our patients, we strive to extend survival in some of the most aggressive forms of cancer.”